News

Article

BioPharm International Sponsored eBooks

BioPharm International Sponsored eBooks-08-20-2025
Volume

Quality and Regulations eBook–August 2025

Articles in this issue
Quality and Regulations eBook–August 2025

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
The front of the REGENXBIO facility in Rockville, Montgomery County, Maryland. REGENXBIO is a biotechnology company researching Adeno-Associate Virus (AAV) gene therapy | Image Credit: © MJ Kerr - stock.adobe.com
August 20th 2025

FDA Extends Review Period for REGENXBIO Hunter Syndrome Treatment

Patrick Lavery
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 20th 2025

The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game

G-CON
Site Logo
August 20th 2025

Benefits of Wireless Continuous Monitoring Systems

Mesa Labs
Mastering Antibody-Drug Conjugates
August 20th 2025

Mastering Antibody-Drug Conjugates

BIOVECTRA
Indianapolis, Indiana, USA - June 13, 2024: The exterior of the Eli Lilly and Company headquarters. Eli Lilly and Company is an American pharmaceutical company. | Image Credit: © Katherine Welles - stock.adobe.com
August 20th 2025

Lilly Statement: MFN Pricing Targeted for September 1, Pushback on Pharma Tariffs

Patrick Lavery
Human papillomavirus infection. Virus. HPV is the most common sexually transmitted infection globally. HPV infection is caused by human papillomavirus, a DNA virus from the papillomavirus family, 3d | Image Credit: © Naeblys - stock.adobe.com
August 20th 2025

FDA Approves Precigen’s Immunotherapy to Treat Recurrent Respiratory Papillomatosis

Patrick Lavery
© 2025 MJH Life Sciences

All rights reserved.